PTJ
PHAT icon

Paul Tudor Jones’s Phathom Pharmaceuticals PHAT Stock Holding History

Paul Tudor Jones’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,225
Closed -$425K – 4103
2026
Q1 		$425K Buy
38,225
+9,671
+34% +$122K ﹤0.01% 2923
2025
Q4 		$474K Sell
28,554
-5,536
-16% -$79.1K ﹤0.01% 2750
2025
Q3 		$401K Buy
+34,090
New +$352K ﹤0.01% 2809
2025
Q1 		– Sell
-34,049
Closed -$276K – 3526
2024
Q4 		$276K Sell
34,049
-2,334
-6% -$28.9K ﹤0.01% 2633
2024
Q3 		$658K Buy
+36,383
New +$509K ﹤0.01% 1859

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Paul Tudor Jones's PHAT Position: Q2 2026 in Review

Paul Tudor Jones sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 38,225 shares — an estimated $425K sold.

Paul Tudor Jones first reported a position in PHAT in Q3 2024 and held it in 5 quarters. The position peaked at $658K in Q3 2024. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Paul Tudor Jones reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 38,225 Phathom Pharmaceuticals shares in Q2 2026, an estimated $425K.
  • Paul Tudor Jones first reported a position in Phathom Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Paul Tudor Jones's Phathom Pharmaceuticals position peaked at $658K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.